NASDAQ
TGTX
Last Price
US $48.74
KEY FIGURES
MKT CAP
$7.5B
EPS
TTM
$3.11
PEG
TTM
0.03x
P/E
TTM
15.65x
P/S
TTM
8.64x
YIELD
0.00%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
72.30%
Return on equity
ROIC: 9.93%
Valuation History
16.3X
Price to Earnings
EV/EBITDA: 57.6X
Cash flow
Profit margin
426.73%
(FY vs FY)
EBITDA Y/Y
-
(FY vs FY)
Cash flow Y/Y
53.78%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $48.74
—
Default assumptions
EBITDA Multiple
Fair Value
Market $48.74
-90.23%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
TG Therapeutics, Inc. cash flow to debt ratio of -9.50% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
TG Therapeutics, Inc.'s free cash flow has increased -38.40% from $-40.56M last year to $-24.99M, signaling increasing performance
Financial risk - Healthy debt to equity ratio.
TG Therapeutics, Inc.'s debt to equity ratio is 1.25, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial risk - Healthy debt to equity ratio development.
TG Therapeutics, Inc.'s debt has increased relative to shareholder equity from 1.14 last year to 1.25 today, signaling weakened financials
Financial stability - Net debt/EBITDA.
TG Therapeutics, Inc. has a net debt to EBITDA ratio of 1.35x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
TG Therapeutics, Inc.'s interest coverage ratio of 3.64 indicates that earnings with good margin can cover interest payments on company debt
Financial stability - Profit margin growth.
TG Therapeutics, Inc.'s profit margin has increased (676.93%) in the last year from 7.11% to 55.22%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
TG Therapeutics, Inc.'s short-term assets of $630.76M exceed its short-term liabilities of $153.76M
Increasing performance - ROA.
TG Therapeutics, Inc.'s return on assets of 26.93% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
TG Therapeutics, Inc.'s return on equity of 72.30%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
TG Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Increasing performance - Earnings stability.
TG Therapeutics, Inc. had positive net income in 3.00 out of 5 years, indicating stable and consistent earnings
Decreasing performance - Free cash flow.
TG Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
TG Therapeutics, Inc. has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
TG Therapeutics, Inc.'s yearly earnings has increased 1.81K% since last year from $23.38M to $447.18M, signaling increasing performance
Increasing performance - Healthy revenue growth.
TG Therapeutics, Inc.'s yearly revenue has increased 87.32% since last year from $329.00M to $616.29M, signaling increasing performance
Increasing performance - ROIC.
ROIC 9.93% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.
Increasing performance - 3-year revenue CAGR.
TG Therapeutics, Inc.'s 3-year revenue CAGR of 504.86% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
TG Therapeutics, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
TG Therapeutics, Inc. had positive ROE in 3.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
TG Therapeutics, Inc. has insufficient data to evaluate this check.
Undervalued - Earnings yield.
TG Therapeutics, Inc. has an earnings yield of 6.39%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Overvalued - EBITDA valuation.
TG Therapeutics, Inc. is overvalued relative to its fair value price of 4.76 based on EBITDA multiple model
Overvalued - EV/EBITDA.
TG Therapeutics, Inc. has an EV/EBITDA ratio of 56.88x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings
Undervalued - PEG ratio value.
TG Therapeutics, Inc. has a PEG-ratio under 1 which is considered undervalued
Overvalued - P/B ratio.
TG Therapeutics, Inc. has a price-to-book ratio of 11.44x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Overvalued - P/S ratio.
TG Therapeutics, Inc. has a price-to-sales ratio of 8.64x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue